Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors

Complete title: ADVL1416, A Phase 1 study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid tumors, including CNS Tumors

Research Study Number ADVL1416
Principal Investigator Julie Park, MD
Phase I

Research Study Description

The main purpose of this study is to evaluate the safety of the study drug known as ramucirumab in children with recurrent or refractory solid tumors including central nervous system (CNS) tumors.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number ADVL1416
Contact Advanced Therapeutics Study Line
Telephone 206/987-2553

Keywords: Brain Cancer; Central Nervous System (CNS); Pediatric Cancers, Miscellaneous; Solid Tumors; Neoplasms; Immunotherapy

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials